HC Wainwright Reiterates Rating on Humacyte, Inc. $HUMA
Key Points
- HC Wainwright now rates Humacyte, Inc. ($HUMA) "buy" with a $4.00 target.
- The Street's average $HUMA price target is $2.10 (Buy).
- $HUMA last traded around $1.08.
HC Wainwright reiterated its rating on Humacyte, Inc. ($HUMA) to a "buy" rating, with a price target of $4.00 in a recent research note.
Humacyte, Inc. ($HUMA) Stock
Humacyte, Inc. Earnings
Analysts Set New Price Targets
About Humacyte, Inc.
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.